Viet
ELITE MEMBER
- Joined
- Jun 18, 2012
- Messages
- 29,950
- Reaction score
- 0
- Country
- Location
The Hanoi Medical University has started the first phase of clinical trials of COVID-19 vaccine ARCT-154 with the participation of 100 volunteers.
The clinical trials will be carried out in three phases with the participation of 21,000 volunteers, including 100 in phase one, 300 in phase two and 20,600 in phase three. (Photo: VNA)
ARCT-154, a mRNA vaccine developed by US company Arcturus Therapeutics, Inc, which transferred the technology to a company in Vietnam. (Photo: VNA). (Photo: VNA)
ARCT-154 is a self-amplifying mRNA vaccine designed to act against coronavirus variants, including the Delta. (Photo: VNA)
ARCT-154 is the third COVID-19 vaccine put into human clinical trials in Vietnam and the first developed with mRNA technology.
The clinical trials will be carried out in three phases with the participation of 21,000 volunteers, including 100 in phase one, 300 in phase two and 20,600 in phase three. (Photo: VNA)
ARCT-154, a mRNA vaccine developed by US company Arcturus Therapeutics, Inc, which transferred the technology to a company in Vietnam. (Photo: VNA). (Photo: VNA)
ARCT-154 is a self-amplifying mRNA vaccine designed to act against coronavirus variants, including the Delta. (Photo: VNA)
ARCT-154 is the third COVID-19 vaccine put into human clinical trials in Vietnam and the first developed with mRNA technology.
